Sugi Predict

Sugi Predict / Compounds / SCHEMBL782851

SCHEMBL782851

SCHEMBL782851

O=c1cnc2cc(Br)ccc2[nH]1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RPS6KA3 P51812 3/20 0.64
▸ CSNK2A1 P68400 2/20 0.64
▸ MAPKAPK2 P49137 1/20 0.64
▸ PLK3 Q9H4B4 1/20 0.64
▸ ALDH1A1 P00352 2/20 0.57
▸ PIM1 P11309 3/20 0.43
▸ CHEK1 O14757 2/20 0.43
▸ FLT3 P36888 2/20 0.43
▸ AURKA O14965 2/20 0.43
▸ DAPK3 O43293 2/20 0.43
▸ JAK2 O60674 2/20 0.43
▸ PRKD3 O94806 2/20 0.43
▸ MAP4K4 O95819 2/20 0.43
▸ PAK4 O96013 2/20 0.43
▸ ABL1 P00519 2/20 0.43
▸ NTRK1 P04629 2/20 0.43
▸ RET P07949 2/20 0.43
▸ MET P08581 2/20 0.43
▸ PDGFRB P09619 2/20 0.43
▸ FGFR1 P11362 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622295 0.85 RPS6KA3 (0.50) RPS6KA3CSNK2A1MAPKAPK2PLK3ALDH1A1
SCHEMBL29591452 0.85 RPS6KA3 (0.50) RPS6KA3CSNK2A1MAPKAPK2PLK3ALDH1A1
SCHEMBL6616116 0.80 RPS6KA3 (0.50) RPS6KA3CSNK2A1MAPKAPK2PLK3ALDH1A1
SCHEMBL19519842 0.78 MAPKAPK2 (0.64) RPS6KA3CSNK2A1MAPKAPK2PLK3ALDH1A1
SCHEMBL2619271 0.78 RPS6KA3 (0.64) RPS6KA3CSNK2A1MAPKAPK2PLK3ALDH1A1
SCHEMBL706811 0.78 MAPKAPK2 (0.64) RPS6KA3CSNK2A1MAPKAPK2PLK3ALDH1A1
SCHEMBL7757513 0.78 RPS6KA3 (0.64) RPS6KA3CSNK2A1MAPKAPK2PLK3ALDH1A1
SCHEMBL31214307 0.77 RPS6KA3 (0.53) RPS6KA3CSNK2A1MAPKAPK2PLK3ALDH1A1
SCHEMBL18142274 0.75 MAPKAPK2 (0.60) RPS6KA3CSNK2A1MAPKAPK2PLK3ALDH1A1
SCHEMBL708539 0.75 MAPKAPK2 (0.60) RPS6KA3CSNK2A1MAPKAPK2PLK3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4720040-A1 SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT Lario Therapeutics Limited (GB) 2026-04-08 — — EP disclosed
WO-2024246522-A1 SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT LARIO THERAPEUTICS LIMITED (GB) 2024-12-05 — — WO disclosed
CN-119060045-A Thiazole urea derivative and application thereof 杭州百新生物医药科技有限公司 2024-12-03 — — CN disclosed
CN-118994040-A Method for preparing 3-aminoquinoxaline-2 (1H) -ketone compound by photocatalysis 南京工业大学 2024-11-22 — — CN disclosed
CN-115135636-B Quinoxalinone derivatives as irreversible inhibitors of KRAS G12C muteins 北京泰德制药股份有限公司 2024-08-23 — — CN disclosed
US-20230373934-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE ESSA PHARMA INC. (CA) 2023-11-23 — — US disclosed
US-20230373934-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE ESSA PHARMA INC. (CA) 2023-11-23 — — US disclosed
US-20230373934-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE ESSA PHARMA INC. (CA) 2023-11-23 — — US disclosed
WO-2023205507-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE ESSA PHARMA INC. (CA) 2023-10-26 — — WO disclosed
US-11731953-B2 Methods and compounds for restoring mutant p53 function PMV PHARMACEUTICALS, INC. (US) 2023-08-22 — — US disclosed
US-20020151531-A1 Contraceptive methods using benzimidazolones LIGAND PHARMACEUTICALS INCORPORATED 2002-10-17 — — US disclosed
US-20020115853-A1 Benzimidazolones and analogues WYETH 2002-08-22 — — US disclosed
US-6423699-B1 CONTRACEPTIVES AMERICAN HOME PRODUCTS CORPORATION 2002-07-23 — — US disclosed
US-6380235-B1 USEFUL AS PROGESTERONE RECEPTOR AGONISTS AND ANTAGONISTS, USED FOR CONTRACEPTION, IN THERAPY OF FIBROIDS, ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER, AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY AMERICAN HOME PRODUCTS CORPORATION 2002-04-30 — — US disclosed
EP-1173423-A1 BENZIMIDAZOLONES AND ANALOGUES AND THEIR USE AS PROGESTERONE RECEPTOR LIGANDS American Home Products Corporation (US) 2002-01-23 — — EP disclosed
WO-2000066564-A1 BENZIMIDAZOLONES AND ANALOGUES AND THEIR USE AS PROGESTERONE RECEPTOR LIGANDS AMERICAN HOME PRODUCTS CORPORATION (US) 2000-11-09 — — WO disclosed
EP-0520024-B1 QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK AS (DK) 1996-06-19 — — EP disclosed
EP-0520024-A1 QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE. NOVO NORDISK AS (DK) 1992-12-30 — — EP disclosed
US-5166155-A Neurological or psychiatric diseases NOVO NORDISK A/S (DK) 1992-11-24 — — US disclosed
WO-1991013878-A1 QUINOXALINE COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1991-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731953-B2 Methods and compounds for restoring mutant p53 function TP53, TP53BP1, HRAS RPS6KA3 1337/4885CSNK2A1 1691/4885MAPKAPK2 1013/4885
US-20020151531-A1 Contraceptive methods using benzimidazolones PGR, GNRHR, NR4A1 RPS6KA3 630/4885CSNK2A1 1301/4885MAPKAPK2 3868/4885
US-20230373934-A1 ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE AR, SHBG, NR5A1 RPS6KA3 2076/4885CSNK2A1 534/4885MAPKAPK2 1907/4885
US-20020115853-A1 Benzimidazolones and analogues PGR, NR5A1, NR3C2 RPS6KA3 933/4885CSNK2A1 477/4885MAPKAPK2 3666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.